21st Annual BIO CEO & Investor Conference Programming Announced

Nov 28 2018
The Biotechnology Innovation Organization (BIO) today announced preliminary programming for the upcoming BIO CEO & Investor Conference to be held February 11-12, 2019 in New York City. Program lineup covers policy, investment, innovation and patient access. New this year, BIO is offering Executive Leadership courses to help companies develop tools for striking deals and improving corporate reputation. Participants will choose between one of two interactive courses which are based on real-life biopharma experiences and will run on Sunday, February 10.

BIO Statement on Unsubstantiated Reports of Heritable Human Genome Editing Experiments in China

Nov 28 2018
The Biotechnology Innovation Organization (BIO) issued the following statement regarding unsubstantiated reports this week of experiments involving heritable human genome editing in China.

BIO Welcomes 21 New Companies to Industrial & Environmental Section

Nov 28 2018
The Biotechnology Innovation Organization today announced 21 companies have joined the Industrial & Environmental Section over the past year. BIO will work closely with these diverse new members as it continues to lead advocacy efforts that advance the development and adoption of biotechnology into industrial and environmental processes, such as the production of bio-based products and biofuels.

BIO Statement on Proposed Changes to Medicare Advantage and Part D Plans

Nov 26 2018
“Today’s proposed rule to roll back critical protections afforded to some of America’s sickest and most vulnerable Medicare beneficiaries would, if adopted, severely limit seniors’ access to the drugs most appropriate for them, and is yet another unfortunate example of Administration proposals that will financially benefit insurance plans and other middlemen in the drug supply chain at the expense of patients."

New Report Shows Global Link Between Pro-Innovation Policies and Biotech Advances

Nov 19 2018

Washington, D.C. (November 19, 2018) – A study released today highlights strategies, policies and best practices that have been successful in...

BIO Releases Third Report in a Series on the State of Innovation in Highly Prevalent Chronic Diseases

Nov 15 2018
Washington, DC (October 26, 2018) – Today, the Biotechnology Innovation Organization (BIO) released a new report, The State of Innovation in Highly Prevalent Chronic Diseases: Volume III Type 2 Diabetes and Obesity Therapeutics, the third in a series on the current funding and R&D landscape for drugs to treat highly prevalent, chronic diseases.

BIO Applauds International Support of Agricultural Applications of Precision Biotechnology

Nov 5 2018
The following statement may be attributed to Joseph Damond, Executive Vice President, International Affairs for the Biotechnology Innovation Organization, in response to the United States and 12 other nations signing on to the International Statement on Agricultural Applications of Precision Biotechnology. The joint statement supports policies that enable agricultural innovation, including genome editing.

BIO Welcomes Announcement of FDA’s Plant and Animal Biotechnology Innovation Action Plan

Nov 1 2018
Washington, D.C. (November 1, 2018) – The Biotechnology Innovation Organization (BIO) released the following statement regarding the U.S. Food and Drug Administration (FDA) Plant and Animal Biotechnology Innovation Action Plan:

BIO Statement on the Administration’s Drug Pricing Proposal

Oct 25 2018
Biotechnology Innovation Organization (BIO) President & CEO James C. Greenwood issued the following statement after the Trump administration outlined proposed changes to the Medicare Part B program.

BIO Applauds President Trump's Directive to Allow Sales of E15 Fuel Year-Round

Oct 9 2018
The following statement may be attributed to Brent Erickson, BIO’s Executive Vice President, Industrial and Environmental Section, in response to President Donald Trump’s directive allowing the sale of E15 fuels year-round.